By Oakley Scan
Published: July 14, 2026
A Breakthrough for End-of-Life Care
In a first-of-its-kind clinical trial, researchers have found that people with agitation and dementia in late life who took a special medical formulation of THC and CBD experienced significantly less agitation compared to those receiving a placebo. The findings were presented July 14, 2026, at the Alzheimer's Association International Conference in London.
The study, dubbed the LiBBY trial (Life's end Benefits of cannaBidiol and tetrahYdrocannabinol), enrolled 120 participants with Alzheimer's disease or other types of dementia who were hospice-eligible and experiencing agitation. The results are nothing short of remarkable: nearly 90% of study participants who received the treatment showed overall improvement after 12 weeks.
"We did not expect these trial results," said Dr. Jacobo Mintzer, co-lead investigator from Georgetown University and Medical University of South Carolina. "They showed a level of response not seen before in clinical trials related to dementia. Rarely do we see close to 90% of patients in a trial respond positively to a new medication."
Why This Matters for Families
Agitation affects many people with late-stage dementia, causing symptoms such as restlessness, aggression, and emotional distress that can profoundly impact patients and their caregivers. Current treatment options are limited and often carry significant side effects.
Laura, whose mother participated in the LiBBY trial, shared what she observed: "She seemed happier. We experienced joy. There were still moments of connection." Her account reflects what many families have long hoped for—a treatment that doesn't wipe out awareness but instead allows patients to remain present and comfortable.
The Study Design
The research team conducted the LiBBY study across 10 U.S. medical centers, with clinical visits taking place entirely in patients' homes or places of residence to avoid the distress of hospital travel for fragile individuals.
Participants were randomly assigned to receive either the active combination or placebo. To ensure unbiased results, neither the participants, their caregivers, nor the clinicians knew who received the active treatment—a rigorous double-blind design.
The mean age of participants was 80 years old, and all were hospice-eligible, meaning they were in the final stages of life. This population particularly needed a fast-acting solution because traditional psychiatric medications often take four to six weeks to build up in the system—far too slow for someone experiencing acute end-of-life distress.
How They Measured Success
Using the Cohen-Mansfield Agitation Inventory (CMAI)—a 29-factor agitation assessment survey—the researchers compared participants at two critical time points: 2 weeks and 12 weeks. Each factor was rated on a 7-point scale from "never" to "several times per hour" by caregivers.
The 2-Week Results
After just 2 weeks, there was a 6.27-point reduction in mean agitation scores in the THC/CBD group compared with the placebo group. This primary outcome was measured early because of the fast-acting nature of the oral oil suspension.
The Clinical Global Impression of Change in Behavior assessment showed that the THC/CBD group was much less agitated at 2 weeks: 83.9% vs 30.5% compared to the placebo group.
The 12-Week Results
At 12 weeks, there was a significant, sustained reduction in agitation. Overall behavioral improvement was achieved by 87.2% of patients treated with THC/CBD versus only 23.6% in the placebo group—a difference that is both statistically and clinically profound.
Safety Profile
One of the most important findings is that the safety profile of the treatment matched placebo. Adverse event rates, such as infections and gastrointestinal disorders, were comparable between groups: 46.7% vs 42.4% (active vs placebo). These are expected occurrences in this patient population and not concerning side effects.
Co-lead investigator Brigid Reynolds, MSN, APRN, ANP-BC, emphasized that current medications like morphine, Valium, and Haldol have had limited effectiveness in treating dementia-related agitation and can cause undesirable side effects. This new approach offers a safer alternative.
A Critical Distinction: Medical vs. Commercial Products
This is where the research team strongly emphasizes a critical distinction. The formulation used in the LiBBY trial is a highly purified, medical-grade pharmaceutical suspension consisting of specific, precisely calibrated ratios of delta-9-THC and CBD dissolved in a fast-acting digestible oil.
"People should not assume that products available at dispensaries or online are equivalent to what was studied in this trial," Reynolds warned. "The medication used in this research was carefully formulated, manufactured, and administered under close medical supervision."
Commercial THC and CBD products sold online or at recreational dispensaries are completely unregulated by clinical trial standards. Their ingredients, quality, and dosing vary wildly. Using unapproved store-bought oils on frail, late-stage dementia patients can be entirely ineffective or even dangerously toxic.
The researchers caution that these clinical benefits cannot be replicated with over-the-counter or dispensary cannabis products due to unregulated purity, dosing, and composition variability.
Why 2 Weeks? The Science of Fast Action
You might wonder: why measure success at just 2 weeks if the study lasted 12 weeks? The answer lies in the formulation itself. Traditional psychiatric medications often take four to six weeks to build up in the system—far too slow for someone experiencing acute end-of-life distress.
This specific oral oil suspension was engineered to digest rapidly, achieving quick absorption and rapid relief. Because of this fast-acting design, the scientists set the primary benchmark at 2 weeks to see if it could deliver immediate emergency relief. The data proved it did, while the 12-week marker confirmed the relief remained stable over time.
What This Means for the Future
The study was funded by a National Institutes of Health cooperative agreement grant (R01AG068324-01) and the Alzheimer's Association. It is being conducted by the NIH-funded Alzheimer's Clinical Trial Consortium and coordinated by the University of Southern California's Epstein Family Alzheimer's Therapeutic Research Institute, the Medical University of South Carolina, and Georgetown University.
The ClinicalTrials.gov ID is NCT05644262, for those interested in following future developments.
"This trial was extremely impressive," Dr. Mintzer noted. "It opens a new door for how we think about managing agitation in end-of-life dementia care."
For families navigating the difficult journey of late-stage dementia, these results offer hope that new treatment options may one day improve quality of life and restore moments of connection, dignity, and calm in their loved ones' final days.
About the Researchers
- Jacobo Mintzer, MD — Georgetown University and Medical University of South Carolina
- Brigid Reynolds, MSN, APRN, ANP-BC — Georgetown University
The full study details are available through the NIH-funded Alzheimer's Clinical Trial Consortium.
Source: Neuroscience News (July 14, 2026). Study funded by NIH cooperative agreement grant R01AG068324-01 and Alzheimer's Association.
